Trial reportESMO open2026
Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.
Trial report in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing personalised oncologic care for older adults with head and neck cancer through structured international collaboration.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab, combined with platinum-5-FU or as a monotherapy, is the standard treatment of patients with recurrent and/or metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC). This treatment is used exclusively in programmed death-ligand 1 (PD-L1)-positive patients in Europe, whereas it is used in the USA regardless of PD-L1 status. However, substantial toxicities, notably those related to cisplatin-based chemotherapy, preclude the use of combination therapy in fragile patients. We investigated the efficacy and tolerance of first-line durvalumab combined with weekly carboplatin/paclitaxel in R/M HNSCC patients who were ineligible for cisplatin. PATIENTS AND
methodsThis prospective multicenter single-arm phase II study assessed tolerance in R/M HNSCC patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0-1 (run-in phase study feasibility, then cohort A) and ECOG-PS 2 (cohort B), frail, not eligible for standard cisplatin-based chemotherapy. In the first-line, patients received four 28-day chemotherapy cycles (carboplatin AUC2; paclitaxel 80 mg/m
resultsFrom 16 May 2019 to 4 March 2021, 64 patients with an ECOG-PS of 1 (cohort A) from 13 French authorized centers (hospital, cancer centers) were included and received study treatments. Cohort B enrolled 40 patients with an ECOG-PS of 2 from 25 Aug 2021 and 9 March 2023 and 39 were assessable. With 40 patients with an ECOG-PS of 0-1 [62.5%, unilateral 95% confidence interval (CI) 51.5%-∞], and 20 patients with an ECOG-PS of 2 (51.3%, unilateral 95% CI 37.1%-∞) alive at 12 months, the study met its primary endpoints.
conclusionsThe promising results in frail patients with an ECOG-PS of 0-1 and 2 encourages further investigation of durvalumab with weekly carboplatin/paclitaxel in first-line R/M HNSCC patients in a comparative phase III clinical trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.